Bryce Linsenmayer focuses his practice on securities law and mergers and acquisitions. He advises issuers and investment bankers in public offerings and domestic and foreign private placements of debt and equity securities, and is involved in negotiating and closing mergers, acquisitions and strategic partnerships.
Bryce also advises on general corporate planning, including domestic and international public and privately held companies, primarily in the energy, health care, environmental, insurance and tech industries. He offers in-depth experience with public offerings on the New York Stock Exchange, NASDAQ and The London Stock Exchange, particularly on the AIM Market for smaller cap companies.
In his third decade of practice, Bryce is known for his unwavering pragmatism and steadfast business focus in transactions, corporate governance issues and overall business planning initiatives. A proven collaborator and empathetic listener, Bryce is valued for his team-spiritedness and commitment to achieving the best result.
Recommended in The Legal 500
U.S. for his work in the M&A/Corporate and Commercial markets, Bryce primarily acts as principal outside counsel to his clients, assisting them across the broad spectrum of their transactional legal needs. Bryce is a contributor to A Practitioners’ Guide to the AIM Rules
(Thomson-London, 2014). Having negotiated and closed deals ranging from hundreds of millions of dollars to more than a billion dollars, Bryce understands
every component of a transaction, and thrives in serving as a catalyst for realizing each clients’ specific goals.
Bering Omega Community Services, Board of Directors (2006 to 2012, 2014 to 2016), former chairman (2009 to 2011)
Friends of St. Paul's Cathedral, London
Represented a European private equity firm in its formation and acquisition of oil and gas assets in Texas.
Represented an upstream oil and gas company in forming a master limited partnership (MLP) and its subsequent initial public offering on the New York Stock Exchange.
Advised a national insurance brokerage firm it its acquisitions of $900 million in insurance brokerage assets.
Lead counsel to the independent directors of MLP general partners in property acquisitions through various drop downs aggregating $750 million.
Represented a number of oil and gas exploration and production companies in their IPOs on the AIM Market of The London Stock Exchange.
Represented a seismic technology company in its IPO on the New York Stock Exchange and subsequent public notes offering.
Represented a multinational insurance brokerage house in connection with its acquisition programs in Europe, Asia and the United States.
Represented an investment banking firm in its underwriting of the initial public offering of a national telecommunications service provider.
Represented a natural gas exploration and development company in the placement of $450 million of its senior notes and its subsequent S-4 exchange offer.
Represented a publicly held oilfield services company in its disposition of one of its divisions to a European conglomerate.
Represented a national food service supplier in its national acquisition program of over $500 million in assets.
Represented an Internet-based travel company in its strategic alliance with a global Internet service provider and an international travel service provider.
Represented two European manufacturers in their acquisition of a U.S. distributor.
Represented a publicly held waste disposal company in its acquisition program, consisting of 20 privately held companies in the U.S. Midwest.
Served as counsel to a special committee of a public company's directors in an interested party transaction concerning the transfer of $1.2 billion in assets.
Served as primary counsel to a number of private equity funds in their formation and acquisition programs.
Represented a German generic pharmaceutical manufacturing company in its strategic acquisition program and eventual sale to Pfizer.
Represented a pharmaceutical manufacturer with operations in the UK and Ireland in their licensing program with Eli Lilly.
Represented an international pharmaceutical manufacturer in their purchase of a generic pharmaceutical company in India.
Represented an international pharmaceutical distribution company in its merger with a large U.S. pharmaceutical manufacturer.